Questcor announces prelim 2nd-qtr results
USA-based drugmaker Questcor Pharmaceuticals has announced preliminary financial results for the three months ending June 30, 2008. The firm predicts revenue of between $23.0 million and $24.0 million, with earnings per share of between $0.09 and $0.11.
Common stock repurchase scheme
During the quarter, the company purchased 1.2 million shares of its common stock under a share repurchase plan at a total cost of $5.6 million. So far in 2008, it has repurchased a total 2.7 million shares of its common stock for $11.8 million and all of the firm's outstanding series A preferred stock for $10.3 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze